- Home
- EML vs STTK Comparison
EML vs STTK Comparison
Compare EML & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- STTK
- Stock Information
- Founded
- EML 1858
- STTK 2016
- Country
- EML United States
- STTK United States
- Employees
- EML N/A
- STTK N/A
- Industry
- EML Industrial Machinery/Components
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- STTK Health Care
- Exchange
- EML Nasdaq
- STTK Nasdaq
- Market Cap
- EML 146.7M
- STTK 83.8M
- IPO Year
- EML N/A
- STTK 2020
- Fundamental
- Price
- EML $24.98
- STTK $1.79
- Analyst Decision
- EML
- STTK Hold
- Analyst Count
- EML 0
- STTK 6
- Target Price
- EML N/A
- STTK $2.67
- AVG Volume (30 Days)
- EML 13.2K
- STTK 1.5M
- Earning Date
- EML 11-04-2025
- STTK 11-13-2025
- Dividend Yield
- EML 1.75%
- STTK N/A
- EPS Growth
- EML N/A
- STTK N/A
- EPS
- EML N/A
- STTK N/A
- Revenue
- EML $269,054,445.00
- STTK $2,997,000.00
- Revenue This Year
- EML $1.56
- STTK N/A
- Revenue Next Year
- EML $7.00
- STTK N/A
- P/E Ratio
- EML $14.21
- STTK N/A
- Revenue Growth
- EML 1.30
- STTK N/A
- 52 Week Low
- EML $19.06
- STTK $0.69
- 52 Week High
- EML $35.03
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- EML 58.53
- STTK 66.00
- Support Level
- EML $23.50
- STTK $1.68
- Resistance Level
- EML $25.46
- STTK $2.01
- Average True Range (ATR)
- EML 0.70
- STTK 0.20
- MACD
- EML 0.16
- STTK 0.07
- Stochastic Oscillator
- EML 79.57
- STTK 77.68
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.